The FDA has banned the OTC products of a small Canadian drugmaker after discovering it was using ingredients from a supplier already on its import alert list. More: FDA bans Canadian OTC firm's products, issues it a warning letter Source:
read moreHeading into Allergan’s third-quarter conference call, executives knew investors were skittish about the prospect of Restasis generics. So they spelled out their solution loud and clear: Cost cuts are coming, and “rapidly.” More: Cost cuts are coming for Allergan, CEO
read morePick up one, cast off another. Just as Novartis agreed to buy a radiotherapy company, it’s reportedly considering a selloff of its generic dermatology products, a once-hot field that’s been hit by pressure on copycat drug prices. And some big-name
read moreWhen Pfizer was preparing to shell out $15 billion for regulatory-challenged Hospira, executives assured investors and regulators that they had the skills to quickly resolve issues at the plants of the sterile injectables specialist. But it has turned out to
read moreNow that Bristol-Myers Squibb’s Opdivo has safely posted growth in 2017, all eyes are on what the drug can pull off next year. Its move into a larger kidney cancer market will be central to that equation. More: Bristol-Myers Squibb
read moreThe National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances. More: NICE back Roche’s Tecentriq for CDF Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals